Browse articles from EyeWorld.org related to glaucoma. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
➤ Phase 2 trial is the ‘first and only’ to show vision improvement for Stargardt disease ➤ IND accepted for retinal disease gene therapy and Phase 1/2 trial to begin ➤ First patients dosed in trial evaluating retinitis pigmentosa treatment ➤ LASIK alternative being researched ➤ Partnership news ➤ ASCRS news and events
➤ FDA approves aceclidine-based drop for presbyopia ➤ Long-term data supports efficacy of continuous wet AMD treatment ➤ First patient dosed in trial for drug eluting lacrimal canaliculus plug ➤ Acquisition news ➤ ASCRS news and events
➤ Topline Phase 2 results for drug treating neuropathic corneal pain ➤ Phase 3 blepharitis treatment doesn’t meet primary endpoint ➤ Study: therapeutic potential of collagen mimetic peptides for myopia ➤ FDA accepts NDA resubmission for dry eye therapy ➤ Partnership news ➤ ASCRS news and events
Several physicians discussed the benefits they see with virtual reality visual fields in practice and the potential for artificial intelligence in glaucoma.
Manjool Shah, MD, shared his thoughts on the topics of the Glaucoma articles: the often-asked question about the impact of lifestyle modifications, the increasingly critical imperative of sustainability in practices, and the rapidly advancing world of virtual visual fields and artificial intelligence.
An emphasis on sustainability in healthcare has gained momentum in recent years. In this article, a group of glaucoma specialists who are experts in sustainability offered their perspectives on how to make meaningful changes in a clinical practice.
➤ Results from second Phase 3 pivotal trial for presbyopia drop ➤ Interim Phase 2 data presented on DME, wet AMD treatment ➤ Phase 2 trial to investigate oral DME treatment ➤ First patient dosed in investigational cell therapy for photoreceptor diseases ➤ Phase 1 trial begins for minimally invasive dry AMD treatment ➤ Acquisitions and other company news ➤ ASCRS news and events
While the treatment mainstays for lowering and/or maintaining a target IOP are achieved with surgery, laser, or pharmaceuticals, patients often ask what else they can do. Several physicians spoke to EyeWorld about lifestyle changes that they recommend as an addition to traditional glaucoma therapies.
➤ Initial Phase 3 results for dry eye disease therapy ➤ Positive Phase 2 results for intravitreal implant for glaucoma and diabetic retinopathy ➤ Phase 1/2a results from allogenic cell therapy for geographic atrophy ➤ Phase 1 trial successful with oral treatment for non-proliferative diabetic retinopathy ➤ ASCRS news and events
➤ Preservative-free fixed-dose combination therapy for glaucoma in development ➤ Rare Pediatric Disease designation granted to investigational Stargardt gene therapy ➤ First patient dosed in genome editing program for corneal dystrophy ➤ ASCRS news and events